Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalGMED -4.83%96 Return-on-Tangible-Equity is 20.02% as of Mar. 2026, which is 50% above its 10-year median of 13.34. GuruFocus rates GMED with a GF Score™ of 96/100 and a GF Value™ of $98.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Globus Medical ranks better than 87.75% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Globus Medical's annualized net income for the quarter that ended in Mar. 2026 was $497 Mil. Globus Medical's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $2,483 Mil. Therefore, Globus Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.02%.
The historical rank and industry rank for Globus Medical's Return-on-Tangible-Equity or its related term are showing as below:
GMED'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.74 Med: 13.34 Max: 26.42
Current: 26.42
During the past 13 years, Globus Medical's highest Return-on-Tangible-Equity was 26.42%. The lowest was 5.74%. And the median was 13.34%.
GMED's Return-on-Tangible-Equity is ranked better than 87.75% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs GMED: 26.42
Globus Medical (NYSE:GMED) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Globus Medical Return-on-Tangible-Equity Related Terms
Globus Medical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Globus Medical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GMED vs PEN, PODD, BRKR: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Globus Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Globus Medical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.02% mean?
Globus Medical (GMED) has a Return-on-Tangible-Equity of 20.02% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Globus Medical and its competitors. This is 50% above median its historical median of 13.34. Over the past decade, Globus Medical's Return-on-Tangible-Equity has ranged from 5.74 to 26.42. According to the industry distribution chart, Globus Medical ranks #93 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 12.3%.
Is Globus Medical's Return-on-Tangible-Equity too high?
Globus Medical's current Return-on-Tangible-Equity of 20.02% is 50% above median its 10-year median of 13.34. Over the past 10 years, this metric has ranged from a low of 5.74 to a high of 26.42. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. Globus Medical's value of 20.02% is 395.5% above this industry median. Based on the distribution chart, Globus Medical ranks #93 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Globus Medical has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's Return-on-Tangible-Equity compare to PEN and PODD?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #93 out of 759 companies for Return-on-Tangible-Equity. This places Globus Medical in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.04. Globus Medical's value of 20.02% is 395.5% above this benchmark. Historically, Globus Medical's own Return-on-Tangible-Equity has ranged from 5.74 to 26.42 over the past decade. While the company's 10-year median is 13.34 vs. the industry median of 4.04, Globus Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current Return-on-Tangible-Equity of 20.02% is 395.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current Return-on-Tangible-Equity is 20.02%, which is 50% above median its own 10-year median of 13.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.78, compared to a current price of $77.00 — trading 22% below its estimated fair value. The current Return-on-Tangible-Equity is 20.02%, which is 50% above median its 10-year median of 13.34 and 395.5% above the Medical Devices & Instruments industry median of 4.04. Globus Medical's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Globus Medical (GMED), the current Return-on-Tangible-Equity is 20.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (GMED) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of $77.00 is trading 22% below its estimated GF Value™ of $98.78.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for GMED:
Return-on-Tangible-Equity: 20.02% (50% above median its 10-year median of 13.34)
GF Value™: $98.78 vs. price of $77.00 (22% below fair value)
Industry Position: 395.5% above the Medical Devices & Instruments median (#93 of 759)
No single metric tells the full story. See the GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
96GF Score
Get the complete analysis for GMED
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GMED has been successfully added to your 
